ERBB2 and breast carcinoma: Other similar predictive biomarkers also exist in other cancers, such as the detection of oestrogen and progesterone receptor expression to predict the response to hormone therapies in breast cancer [51], and the detection of HER-2 to predict the response to trastuzumab therapy, also in breast cancer [52,53].